AAV Vector Design
Unlike plasmid vectors, AAV can package only a limited amount of foreign DNA. The wild-type genome is about 4.7 kb, which serves as the reference for recombinant vector design. Exceeding this range can reduce packaging efficiency, lower the full-length genome fraction, and impair transgene expression.
See the ConsequencesDiscuss Your ConstructCapacity
A common mistake is to equate the gene of interest with the payload. The relevant number is the full cassette length between the two ITRs.
A typical expression cassette includes the promoter, gene of interest, regulatory elements, and poly(A) signal. All of these sequences between the ITRs must be counted. A 3 kb gene can still exceed capacity once a large promoter and regulatory elements are added.
The 4.7 kb figure derives from the wild-type AAV genome. It is a design reference, not a physical cutoff. Slightly oversize vectors can still package, but efficiency and full-length fraction degrade as length increases.
Over-Capacity Effects
Exceeding the practical capacity does not usually stop packaging entirely; it degrades the quality of what is produced.
As cassette length approaches or exceeds the reference range, the efficiency of packaging intact genomes falls, lowering overall vector yield.
Oversize vectors produce more truncated or incomplete genomes, so genome titer alone can overstate the amount of functional vector.
Length variation and truncation fragments complicate the genome population and can make quality analysis more difficult.
If a fraction of genomes lacks the complete expression cassette, transduction may fail to produce the intended protein, giving low expression despite a high titer.
Diagnosis
This is a common point of confusion. qPCR and ddPCR usually target a short region of the vector, so they detect the presence of that region, not the integrity of the whole cassette.
| Question | What the titer tells you | What it does not tell you |
|---|---|---|
| Is the genome present? | qPCR/ddPCR detects the targeted sequence, giving a genome titer for that region. | It does not prove the full cassette is intact if the probe target lies outside any truncation. |
| Is the cassette full length? | Requires genome-integrity analysis, not just a single-region titer. | Truncation outside the probe region can still yield a high nucleic-acid titer. |
| Is the vector functional? | Requires transduction or expression assessment in a relevant cell system. | High vg/mL does not equal a high fraction of functional, full-length genomes. |
Integrity
Because titer does not equal full-length genome, near-capacity vectors benefit from an explicit integrity assessment.
| Method | What it measures | Why it matters for oversize vectors |
|---|---|---|
| Alkaline agarose gel | Full-length versus truncated single-stranded genomes. | Directly visualizes the distribution of genome sizes produced by an oversize vector. |
| Multi-region qPCR/ddPCR | Presence of multiple regions across the cassette. | Detects truncation by comparing signals at different positions along the genome. |
| Long-read sequencing | Full-length packaged genome sequence. | Resolves the actual genome population, including truncation and heterogeneity. |
| Transduction assay | Functional transgene expression. | Confirms that intact genomes translate into biological activity. |
Solutions
For a gene that is too large for a single AAV, the options are to shrink the cassette or to split the delivery.
Use a more compact promoter or smaller regulatory elements to reduce overall cassette length. Element shortening can affect expression strength, specificity, or duration, so it must be weighed against the study goal.
Delete sequences that are not required for function to free capacity for the gene of interest.
For large genes, a dual AAV strategy splits the expression framework into two vectors and reconstitutes the full framework after co-delivery using overlapping sequences, trans-splicing, or related designs. Effectiveness depends on construct design, co-transduction efficiency, and intracellular reconstitution.
Payload Strategies
The best approach depends on the gene size, the required expression, and the tolerance for reduced efficiency.
| Strategy | How it works | Trade-offs |
|---|---|---|
| Compact single AAV | Shrink the cassette with a minimal promoter and trimmed regulatory elements. | May reduce expression strength, specificity, or duration. |
| Dual AAV — trans-splicing | Split the coding sequence across two vectors and reconstitute via splicing after co-transduction. | Depends on co-transduction and splicing efficiency; lower overall yield than a single vector. |
| Dual AAV — overlapping | Two vectors carry overlapping sequence that recombines into a full expression unit. | Requires overlap design and efficient recombination or hybrid formation. |
| Alternative vectors | Use a different delivery system for very large payloads. | May not match the expression, persistence, or safety profile of AAV. |
Design Workflow
Capacity should be evaluated at the design stage, not after production.
Enumerate the promoter, gene, regulatory elements, and poly(A) between the ITRs.
Calculate the full ITR-to-ITR length, not just the gene of interest.
Judge whether the cassette is within, near, or over the ~4.7 kb reference.
Compact the promoter or trim non-essential sequence where possible.
For large genes, evaluate a dual AAV or split-delivery approach.
After production, confirm full-length genome fraction and function, not just titer.
Project Support
Creative Biolabs provides AAV design and production capabilities that can be scoped around your payload size and delivery strategy.
Configure a cassette that fits the packaging capacity for your transgene.
Explore strategies for delivering large transgenes that approach or exceed single-AAV capacity.
Use the compact self-complementary format for small expression units.
Plan editing cassettes with capacity in mind when carrying Cas and guide elements.
Produce vector under a defined process and assess packaging efficiency.
Confirm genome integrity and sequence after packaging.
References
FAQ
Share your transgene size, expression cassette, and delivery goals. Creative Biolabs can help assess capacity and recommend a compact or dual-AAV strategy.
Inquiry NowTell us about your project, and our experts will get back to you with a customized quote and proposal.
